AC
ELTX icon

Aristides Capital’s Elicio Therapeutics ELTX Stock Holding History

Aristides Capital’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,514
Closed -$102K – 217
2021
Q4 		$102K Buy
+3,514
New +$178K 0.05% 240

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aristides Capital's ELTX Position: Q1 2022 in Review

Aristides Capital sold out of Elicio Therapeutics (ELTX) in Q1 2022, closing a stake of 3,514 shares — an estimated $102K sold.

Aristides Capital first reported a position in ELTX in Q4 2021 and held it in 1 quarter. The position peaked at $102K in Q4 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2022.

  • Aristides Capital reported no remaining Elicio Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Aristides Capital sold 3,514 Elicio Therapeutics shares in Q1 2022, an estimated $102K.
  • Aristides Capital first reported a position in Elicio Therapeutics in Q4 2021 and held it in 1 quarter.
  • Aristides Capital's Elicio Therapeutics position peaked at $102K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2022.

Based on Aristides Capital's 13F filing for Q1 2022, filed 16 May 2022.